Evidence map›Paper›PMID 39132504›Full record

SynthesisFrontiers in oncology2024

Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.

Suleiman Zakari, Nguedia K Niels, Grace V Olagunju, Precious C Nnaji, Oluwabusayo Ogunniyi, Mercy Tebamifor, Emmanuel N Israel, Sunday E Atawodi, Olubanke Olujoke Ogunlana

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  9. Review
  10. Article
  11. Promising Role of PKM2 in the Diagnosis and Prognosis of Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suleiman ZakariDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Nguedia K NielsDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Grace V OlagunjuDepartment of Molecular Biology, New Mexico State University, Las Cruces, NM, United States.
Precious C NnajiDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Oluwabusayo OgunniyiDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Mercy TebamiforDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Emmanuel N IsraelDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.
Sunday E AtawodiDepartment of Biochemistry, Federal University Lokoja, Lokoja, Kogi State, Nigeria.
Olubanke Olujoke OgunlanaDepartment of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a global health challenge, necessitating continuous advancements in diagnostic and treatment strategies. This review focuses on the utility of non-invasive biomarkers in cancer diagnosis and treatment, their role in early detection, disease monitoring, and personalized therapeutic interventions. Through a systematic review of the literature, we identified 45 relevant studies that highlight the potential of these biomarkers across various cancer types, such as breast, prostate, lung, and colorectal cancers. The non-invasive biomarkers discussed include liquid biopsies, epigenetic markers, non-coding RNAs, exosomal cargo, and metabolites. Notably, liquid biopsies, particularly those based on circulating tumour DNA (ctDNA), have emerged as the most promising method for early, non-invasive cancer detection due to their ability to provide comprehensive genetic and epigenetic information from easily accessible blood samples. This review demonstrates how non-invasive biomarkers can facilitate early cancer detection, accurate subtyping, and tailored treatment strategies, thereby improving patient outcomes. It underscores the transformative potential of non-invasive biomarkers in oncology, highlighting their application for enhancing early detection, survival rates, and treatment precision in cancer care. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023474749 PROSPERO, identifier CRD42023474749.

Indexed as

biomarkersbiomarker sensitivitycancer diagnosiscancer treatmentnon-invasive biomarkersor clinical utilityspecificity

Identifiers

PMID39132504
PMCPMC11313249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.